Main Article Content

Abstract

A 2nd-generation selective oestrogen receptor modulator, raloxifene HCl (RLX-HCl) is a non- steroidal benzothiophene that binds to oestrogen receptors. While administer orally due to its extensive first pass metabolism in gut, it possess only 2% absolute bioavailability. In this present work, RLX-HCL was formulated as proniosomes by slurry method, where different ratios of surfactant and cholesterol were used for preparation and evaluating study. The shape of prepared RLX-HCl loaded proniosomes were spherical with an average particle size of 690nm with a high encapsulation efficiency of 83.64%. The study revealed that in 24h, formulation RS606 had the highest cumulative drug release (99.42%). From the stability study, 5°C was identified as the suitable temperature for the optimized proniosomes. In conclusion, an improved bioavailability and prolonged drug release profile of the proniosome formulation seems to be a promising delivery system for RLX-HCl.                         

Keywords

Lipids Drug release Stability study Selective oestrogen receptor modulator

Article Details

How to Cite
Bhama S, Sambathkumar R, & Shanmuga Sundaram R. (2016). Preparation and characterization of raloxifene proniosomes using sorbitan esters . International Journal of Research in Pharmaceutical Sciences, 7(2), 142-149. Retrieved from https://pharmascope.org/ijrps/article/view/1267